Compare FINV & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | INSP |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 2018 |
| Metric | FINV | INSP |
|---|---|---|
| Price | $4.94 | $45.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 16 |
| Target Price | $12.10 | ★ $94.00 |
| AVG Volume (30 Days) | 713.9K | ★ 913.9K |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | N/A | $8.02 |
| Revenue Next Year | $10.58 | $8.11 |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $4.35 | $38.91 |
| 52 Week High | $10.90 | $147.03 |
| Indicator | FINV | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 58.28 |
| Support Level | $4.67 | $39.42 |
| Resistance Level | $5.23 | $58.45 |
| Average True Range (ATR) | 0.17 | 2.07 |
| MACD | 0.00 | 0.70 |
| Stochastic Oscillator | 65.45 | 81.48 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.